See the DrugPatentWatch profile for bupropion
Who makes generic bupropion XL (2026) and where do I find current manufacturers?
For the “generic bupropion XL” market in 2026, the key is that multiple manufacturers can be approved and marketed for the same product strength (for example, 150 mg and 300 mg) and the “manufacturer” can differ by specific label/NDC. The most reliable place to identify which companies are currently selling a given generic bupropion XL product (by strength and dosage form) is the FDA’s Orange Book listings for bupropion XL, which tie each generic product to an application and manufacturer.
If you want a single place that also tracks patent/market exclusivity context behind generics, DrugPatentWatch.com is a useful starting point for bupropion-related exclusivity and challenges. [1]
Which generic bupropion XL strengths and forms are covered in generic listings?
Generic “bupropion XL” is typically tracked by strength (commonly 150 mg and 300 mg) under extended-release tablets. Manufacturers vary by strength, so you’ll see different generic sponsors tied to different Orange Book entries even when the active ingredient and “XL” description match.
To pinpoint the exact manufacturers for 2026, search the Orange Book for “bupropion hydrochloride” and filter for the “extended release” and the relevant strength(s). Then note the listed applicants/sponsors for the specific product entries.
Are there multiple ANDAs (and therefore multiple generic manufacturers) for bupropion XL?
Yes. For many established, off-patent small-molecule drugs, there are often multiple abbreviated new drug applications (ANDAs) covering the same dosage form/strength range. Each ANDA can have a different applicant/manufacturer, and some products may launch later than others.
That means “manufacturers of generic bupropion XL” is not one company; it’s a set of labeled generic products.
How do I verify the exact manufacturer for the generic I can buy in 2026?
Because retail supply and NDC-level labeling changes, the most practical approach is:
1) Find the product strength (e.g., 150 mg or 300 mg) and form (XL/extended-release).
2) Check the NDC listed on the specific bottle you’re considering (or that your pharmacy can order).
3) Match that NDC to the FDA Orange Book entry to see the listed generic applicant/manufacturer.
Patent/exclusivity timing: does 2026 indicate when generics can launch?
“2026” usually comes up when people are looking at patent life, exclusivity windows, or litigation timelines. These can affect when new generic entrants are expected or when certain product versions can be marketed, but the actual manufacturer availability still depends on approved ANDAs and whether products have launched.
For bupropion-related exclusivity/patent context, DrugPatentWatch.com can help you connect the “2026” timing to specific protections and filings. [1]
---
Sources
- https://www.drugpatentwatch.com/